HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. maintains a Buy rating on Entrada Therapeutics (NASDAQ:TRDA) but lowers the price target from $20 to $18.
June 25, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Entrada Therapeutics but lowers the price target from $20 to $18.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100